bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a report released on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. Wells Fargo & Company decreased their price target on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a report on Monday, February 24th. Barclays lowered their price target on bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a report on Monday, March 31st. JPMorgan Chase & Co. raised shares of bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. Finally, Baird R W lowered shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $44.60.

bluebird bio Stock Performance

Shares of NASDAQ BLUE opened at $3.84 on Wednesday. The stock has a market cap of $37.58 million, a PE ratio of -0.10 and a beta of 0.27. bluebird bio has a 1 year low of $3.56 and a 1 year high of $28.60. The firm has a fifty day moving average price of $4.23 and a 200-day moving average price of $6.62. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33.

Hedge Funds Weigh In On bluebird bio

A number of institutional investors and hedge funds have recently made changes to their positions in BLUE. Bank of New York Mellon Corp raised its position in shares of bluebird bio by 12.7% during the 1st quarter. Bank of New York Mellon Corp now owns 32,759 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 3,686 shares in the last quarter. Regeneron Pharmaceuticals Inc. bought a new stake in shares of bluebird bio in the 4th quarter valued at approximately $175,000. Barclays PLC boosted its holdings in shares of bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 184,605 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of bluebird bio by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock worth $2,433,000 after purchasing an additional 166,771 shares during the period. 87.43% of the stock is owned by hedge funds and other institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.